419 related articles for article (PubMed ID: 22435662)
1. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands.
Yano S; Takeuchi S; Nakagawa T; Yamada T
Cancer Sci; 2012 Jul; 103(7):1189-94. PubMed ID: 22435662
[TBL] [Abstract][Full Text] [Related]
2. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Taniguchi H; Takeuchi S; Fukuda K; Nakagawa T; Arai S; Nanjo S; Yamada T; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jan; 108(1):53-60. PubMed ID: 27783866
[TBL] [Abstract][Full Text] [Related]
3. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
5. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
Tanimoto A; Yamada T; Nanjo S; Takeuchi S; Ebi H; Kita K; Matsumoto K; Yano S
Oncotarget; 2014 Jul; 5(13):4920-8. PubMed ID: 24952482
[TBL] [Abstract][Full Text] [Related]
6. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
[TBL] [Abstract][Full Text] [Related]
7. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation.
Nakade J; Takeuchi S; Nakagawa T; Ishikawa D; Sano T; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Matsumoto K; Yonekura K; Yano S
J Thorac Oncol; 2014 Jun; 9(6):775-83. PubMed ID: 24828661
[TBL] [Abstract][Full Text] [Related]
8. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
9. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL
Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954
[TBL] [Abstract][Full Text] [Related]
10. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
11. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF.
Ishikawa D; Takeuchi S; Nakagawa T; Sano T; Nakade J; Nanjo S; Yamada T; Ebi H; Zhao L; Yasumoto K; Nakamura T; Matsumoto K; Kagamu H; Yoshizawa H; Yano S
PLoS One; 2013; 8(5):e62104. PubMed ID: 23690929
[TBL] [Abstract][Full Text] [Related]
12. EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Chang H; Sung JH; Moon SU; Kim HS; Kim JW; Lee JS
Yonsei Med J; 2017 Jan; 58(1):9-18. PubMed ID: 27873490
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
[TBL] [Abstract][Full Text] [Related]
14. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
[TBL] [Abstract][Full Text] [Related]
15. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
Yang H; Wang R; Peng S; Chen L; Li Q; Wang W
Oncotarget; 2016 Mar; 7(13):16273-81. PubMed ID: 26919104
[TBL] [Abstract][Full Text] [Related]
16. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.
Sasaki T; Koivunen J; Ogino A; Yanagita M; Nikiforow S; Zheng W; Lathan C; Marcoux JP; Du J; Okuda K; Capelletti M; Shimamura T; Ercan D; Stumpfova M; Xiao Y; Weremowicz S; Butaney M; Heon S; Wilner K; Christensen JG; Eck MJ; Wong KK; Lindeman N; Gray NS; Rodig SJ; Jänne PA
Cancer Res; 2011 Sep; 71(18):6051-60. PubMed ID: 21791641
[TBL] [Abstract][Full Text] [Related]
17. EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.
De Mello RA; Liu DJ; Aguiar PN; Tadokoro H
Recent Pat Anticancer Drug Discov; 2016; 11(4):393-400. PubMed ID: 27491402
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer.
Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S
J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Nguyen KS; Kobayashi S; Costa DB
Clin Lung Cancer; 2009 Jul; 10(4):281-9. PubMed ID: 19632948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]